A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and
immunogenicity of MRG002 as single agent in HER2-positive unresectable locally advanced or
metastatic biliary tract cancer patients who have progressed during or relapsed after at
least one prior stand therapy.